<table>
<thead>
<tr>
<th>Short Name</th>
<th>Full Title + Study Description</th>
<th>Type</th>
<th>Investigator</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOLO</td>
<td><strong>APOLLO</strong>: Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR System in patients with severe symptomatic mitral regurgitation.</td>
<td>Device</td>
<td>Dr. William Merhi</td>
<td>Elizabeth Helm <a href="mailto:Elizabeth.Helm@spectrumhealth.org">Elizabeth.Helm@spectrumhealth.org</a> 616.486.2080</td>
</tr>
<tr>
<td></td>
<td>Evaluate the safety and efficacy of Medtronic Intrepid™ TMVR System in patients with moderate-to-severe or severe symptomatic mitral regurgitation who, by agreement of the local site multidisciplinary heart team experienced in mitral valve therapies, may not be optimally treated with approved transcatheter repair or surgical mitral valve intervention.</td>
<td></td>
<td>Dr. John Heiser</td>
<td></td>
</tr>
<tr>
<td>The Early Feasibility Study of the TMVR Transseptal System</td>
<td><strong>The Early Feasibility Study of the TMVR Transseptal System:</strong> Evaluation of the Safety and Performance of The Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System with Transfemoral Transseptal access in Patients with Severe, Symptomatic Mitral Regurgitation</td>
<td>Device</td>
<td>Dr. William Merhi</td>
<td>Elizabeth Helm <a href="mailto:Elizabeth.Helm@spectrumhealth.org">Elizabeth.Helm@spectrumhealth.org</a> 616.486.2080</td>
</tr>
<tr>
<td></td>
<td>The study is a prospective, multi-center, non-randomized study to evaluate the safety and performance of The Intrepid™ TMVR System with transseptal access in patients with severe, symptomatic mitral regurgitation, who are ineligible for conventional mitral valve surgery.</td>
<td></td>
<td>Dr. John Heiser</td>
<td></td>
</tr>
<tr>
<td>The Half Moon TMVR Pilot Study</td>
<td><strong>The Half Moon TMVR Pilot Study:</strong> Evaluation of the Safety and Performance of the Half Moon Transcatheter Mitral Valve Repair System in High Risk Patients with Severe, Symptomatic Mitral Regurgitation</td>
<td>Device</td>
<td>Dr. William Merhi</td>
<td>Elizabeth Helm <a href="mailto:Elizabeth.Helm@spectrumhealth.org">Elizabeth.Helm@spectrumhealth.org</a> 616.486.2080</td>
</tr>
<tr>
<td></td>
<td>The study is a prospective, multi-center, single-arm, non-randomized, Early Feasibility Study (EFS) to evaluate the safety and performance of the Half Moon TMVR System in patients with severe, symptomatic mitral regurgitation, who are at high risk for conventional mitral valve surgery.</td>
<td></td>
<td>Rachel Cameron <a href="mailto:Rachel.Cameron@spectrumhealth.org">Rachel.Cameron@spectrumhealth.org</a> 616.391.9360</td>
<td></td>
</tr>
</tbody>
</table>